Abstract:Background: Both Parkinson's disease (PD) and multiple system atrophy (MSA) have associated sleep disorders related to the underlying neurodegenerative pathology. Clinically, MSA with predominant parkinsonism (MSA-P) resembles PD in the manifestation of prominent parkinsonism. Whether the amount of rapid eye movement (REM) sleep without atonia could be a potential marker for differentiating MSA-P from PD has not been thoroughly investigated. This study aimed to examine whether sleep parameters could provide a method for differentiating MSA-P from PD. Methods: This study comprised 24 MSA-P patients and 30 PD patients, and they were of similar age, gender, and REM sleep behavior disorder (RBD) prevalence. All patients underwent clinical evaluation and one night of video-polysomnography recording. The tonic and phasic chin electromyogram (EMG) activity was manually quantified during REM sleep of each patient. We divided both groups in terms of whether they had RBD to make subgroup analysis. Results: No significant difference between MSA-P group and PD group had been found in clinical characteristics and sleep architecture. However, MSA-P patients had higher apnea-hypopnea index (AHI; 1.15 [0.00, 8.73]/h vs. 0.00 [0.00, 0.55]/h, P = 0.024) and higher tonic chin EMG density (34.02 [18.48, 57.18]% vs. 8.40 [3.11, 13.06]%, P < 0.001) as compared to PD patients. Subgroup analysis found that tonic EMG density in MSA + RBD subgroup was higher than that in PD + RBD subgroup (55.04 [26.81, 69.62]% vs. 11.40 [8.51, 20.41]%, P < 0.001). Furthermore, no evidence of any difference in tonic EMG density emerged between PD + RBD and MSA - RBD subgroups (P > 0.05). Both disease duration (P = 0.056) and AHI (P = 0.051) showed no significant differences during subgroup analysis although there was a trend toward longer disease duration in PD + RBD subgroup and higher AHI in MSA - RBD subgroup. Stepwise multiple linear regression analysis identified the presence of MSA-P (&bgr; = 0.552, P < 0.001) and RBD (&bgr; = 0.433, P < 0.001) as predictors of higher tonic EMG density. Conclusion: Tonic chin EMG density could be a potential marker for differentiating MSA-P from PD.

Polysomnographic Findings of Myotonic Dystrophy Type 1/type 2: Evidence from Case-Control Studies.

Myotonic Dystrophy Type 1 (DM1): Clinical Characteristics and Disease Progression in a Large Cohort

Association between Reported Sleep Disorders and Behavioral Issues in Children with Myotonic Dystrophy Type 1—Results from a Retrospective Analysis in Italy

Sleep in multiple sclerosis: a systematic review and meta-analysis of polysomnographic findings

Sleep in Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-Analysis of Polysomnographic Findings

Differential characteristics of repeated polysomnography and multiple sleep latency test parameters in narcolepsy type 1 and type 2 patients: a longitudinal retrospective study

Comparative Polysomnography Parameters Between Narcolepsy Type 1/type 2 and Idiopathic Hypersomnia: A Systematic Review and Meta-Analysis.

Sleep in Huntington's Disease: a Systematic Review and Meta-Analysis of Polysomongraphic Findings.

Tonic Electromyogram Density in Multiple System Atrophy with Predominant Parkinsonism and Parkinson's Disease.

Polysomnographic Changes of Obsessive-Compulsive Disorder: Evidence from Case-Control Studies

Sleep apnoea and hypoventilation in patients with five major types of muscular dystrophy

Congenital and childhood myotonic dystrophy: Current aspects of disease and future directions

Excessive daytime sleepiness in myotonic dystrophy: a narrative review

Greater cortical thinning and microstructural integrity loss in myotonic dystrophy type 1 compared to myotonic dystrophy type 2

Fatigue and daytime sleepiness in patients with myotonic dystrophy type 1: To lump or split?

1022 Sleep in Duchenne Muscular Dystrophy

Clinical and polysomnographic features of patients with multiple system atrophy in Southwest China

The role of noninvasive ventilation in the management of type II respiratory failure in patients with myotonic dystrophy

Central Nervous System Involvement as Outcome Measure for Clinical Trials Efficacy in Myotonic Dystrophy Type 1

Characteristics of polysomnography in children with muscular dystrophy

Latent factors underlying the symptoms of adult-onset myotonic dystrophy type 1 during the clinical course